A2 to O Lung Transplants

Last updated: February 3, 2025
Sponsor: University Health Network, Toronto
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Blood group A2 donor to blood group O recipient lung transplant surgery

Clinical Study ID

NCT05581745
21-5005
  • Ages > 18
  • All Genders

Study Summary

Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • first lung transplant

  • blood group O recipient

  • low pre-operative anti-A antibody titers

  • consent to study participation

Exclusion

Exclusion Criteria:

  • re-transplant

  • multiorgan transplant

  • positive virtual crossmatch at time of transplant

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: Blood group A2 donor to blood group O recipient lung transplant surgery
Phase:
Study Start date:
July 14, 2022
Estimated Completion Date:
December 31, 2033

Connect with a study center

  • Toronto General Hospital, University Health Network

    Toronto, Ontario M5G 2C4
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.